CLX Stock Analysis: The Clorox | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 11.344m USD | 12M Return: -5.6% | US1890541097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 213M
EPS Trend: -0.7%
Qual. Beats: 1
Rev. Trend: -65.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Clorox Company, founded in 1913 and headquartered in Oakland, California, is a multinational manufacturer and marketer of consumer and professional products. The company organizes its operations into four segments: Health and Wellness, Household, Lifestyle, and International, distributing goods across both retail and institutional channels worldwide.
Clorox operates a brand-heavy business model built around a portfolio of iconic household names spanning cleaning and disinfecting products (Clorox, Pine-Sol, Tilex, Formula 409), professional hygiene solutions (Purell, GOJO, CloroxPro), waste and food protection (Glad, Chux, Hidden Valley), pet care (Fresh Step, Scoop Away, Ever Clean), grilling (Kingsford), and natural personal care and water filtration (Burts Bees, Brita). Its products reach consumers through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet, and military stores, as well as e-commerce and direct sales distributors.
As a member of the Consumer Staples sector under the Household Products sub-industry, Clorox benefits from the typically defensive nature of its category, with demand for cleaning, disinfecting, and food-related essentials generally remaining stable through economic cycles. The companys reliance on a wide network of U.S. mass-market retailers makes shelf placement and retailer relationships central to its competitive position.
- Disinfecting category volumes decline as pandemic demand normalizes
- Commodity and pulp input costs pressure gross margins
- International sales face emerging market currency headwinds
| Net Income: 677.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -5.72 > 1.0 |
| NWC/Revenue: -14.22% < 20% (prev -7.96%; Δ -6.26% < -1%) |
| CFO/TA 0.08 > 3% & CFO 662.0m > Net Income 677.0m |
| Net Debt (5.86b) to EBITDA (2.24b): 2.62 < 3 |
| Current Ratio: 0.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (122.0m) vs 12m ago -0.81% < -2% |
| Gross Margin: 41.94% > 18% (prev 44.34%; Δ -2.40% > 0.5%) |
| Asset Turnover: 107.7% > 50% (prev 122.5%; Δ -14.76% > 0%) |
| Interest Coverage Ratio: 12.53 > 6 (EBIT TTM 1.99b / Interest Expense TTM 159.0m) |
| A: -0.13 (Total Current Assets 1.93b - Total Current Liabilities 2.95b) / Total Assets 7.83b |
| B: 0.03 (Retained Earnings 247.0m / Total Assets 7.83b) |
| C: 0.30 (EBIT TTM 1.99b / Avg Total Assets 6.68b) |
| D: -0.01 (Book Value of Equity -39.0m / Total Liabilities 7.71b) |
| Altman-Z'' = 1.25 = BB |
| DSRI: 1.00 (Receivables 745.0m/703.0m, Revenue 7.20b/6.77b) |
| GMI: 1.06 (GM 44.34% / 41.94%) |
| AQI: 1.26 (AQ_t 0.52 / AQ_t-1 0.41) |
| SGI: 1.06 (Revenue 7.20b / 6.77b) |
| TATA: 0.00 (NI 677.0m - CFO 662.0m) / TA 7.83b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of November 05, 2026, the stock is trading at USD 99.16 with a total of 4,505,064 shares traded. Over the past week, the price has changed by +14.19%, over one month by +22.67%, over three months by -2.77% and over the past year by -5.63%.
Current recommended Stop Loss: 95.40 (which is 3.8% or 1.4 ATR below the current price).
The Clorox has received a consensus analysts rating of 2.79. Therefore, it is recommended to hold CLX.
- StrongBuy: 1
- Buy: 0
- Hold: 14
- Sell: 2
- StrongSell: 2
| Analysts Target Price | 97.8 | -1.4% |
P/E Trailing = 16.8705
P/E Forward = 15.083
P/S = 1.6881
P/B = 118.2507
P/EG = 1.1018
Revenue TTM = 7.20b USD
EBIT TTM = 1.99b USD
EBITDA TTM = 2.24b USD
Long Term Debt = 3.98b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.26b USD (from shortTermDebt, last quarter)
Debt = 6.05b USD (from shortLongTermDebtTotal, last quarter) + Leases 452.0m
Net Debt = 5.86b USD (calculated: Debt 6.05b - CCE 184.0m)
Enterprise Value = 17.2b USD (11.3b + Debt 6.05b - CCE 184.0m)
Interest Coverage Ratio = 12.53 (Ebit TTM 1.99b / Interest Expense TTM 159.0m)
EV/FCF = 37.98x (Enterprise Value 17.2b / FCF TTM 453.0m)
FCF Yield = 2.63% (FCF TTM 453.0m / Enterprise Value 17.2b)
FCF Margin = 6.30% (FCF TTM 453.0m / Revenue TTM 7.20b)
Net Margin = 9.41% (Net Income TTM 677.0m / Revenue TTM 7.20b)
Gross Margin = 41.94% ((Revenue TTM 7.20b - Cost of Revenue TTM 4.18b) / Revenue TTM)
Gross Margin QoQ = 40.42% (prev 41.27%)
Tobins Q-Ratio = 2.20 (Enterprise Value 17.2b / Total Assets 7.83b)
Interest Expense / Debt = 2.63% (Interest Expense 159.0m / Debt 6.05b)
Taxrate = 22.33% (199.0m / 891.0m)
NOPAT = 1.55b (EBIT 1.99b * (1 - 22.33%))
Current Ratio = 0.65 (Total Current Assets 1.93b / Total Current Liabilities 2.95b)
Debt / Equity = -155.0 (out of range, set to none) (Debt 6.05b / totalStockholderEquity, last quarter -39.0m)
Debt / EBITDA = 2.62 (Net Debt 5.86b / EBITDA 2.24b)
Debt / FCF = 12.94 (Net Debt 5.86b / FCF TTM 453.0m)
Total Stockholder Equity = 4.75m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.13% (Net Income 677.0m / Total Assets 7.83b)
RoE = 14.3k% (out of range, set to none) (Net Income TTM 677.0m / Total Stockholder Equity 4.75m)
RoCE = 50.00% (EBIT 1.99b / Capital Employed (Equity 4.75m + L.T.Debt 3.98b))
RoIC = 25.98% (NOPAT 1.55b / Invested Capital 5.96b)
WACC = 4.60% (E(11.3b)/V(17.4b) * Re(5.96%) + D(6.05b)/V(17.4b) * Rd(2.63%) * (1-Tc(0.22)))
Discount Rate = 5.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.05 | Cagr: -1.08%
[DCF] Terminal Value 73.10% ; FCFF base≈526.2m ; Y1≈461.4m ; Y5≈372.8m
[DCF] Fair Price = 1.01 (EV 5.98b - Net Debt 5.86b = Equity 122.3m / Shares 120.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -0.65 | EPS CAGR: -0.07% | SUE: 2.19 | # QB: 1
Revenue Correlation: -64.97 | Revenue CAGR: -2.49% | SUE: 0.61 | # QB: 0
EPS current Quarter (2026-12-31): EPS=1.33 | Chg30d=-0.74% | Revisions=-12% | Analysts=14
EPS next Quarter (2027-03-31): EPS=1.51 | Chg30d=-4.20% | Revisions=-42% | Analysts=14
EPS current Year (2027-06-30): EPS=5.71 | Chg30d=-0.69% | Revisions=-77% | GrowthEPS=+3.3% | GrowthRev=+13.6%
EPS next Year (2028-06-30): EPS=6.19 | Chg30d=-0.50% | Revisions=-62% | GrowthEPS=+8.3% | GrowthRev=+2.2%
[Analyst] Revisions Ratio: -66% (up=4, down=25)